Last update 25 Apr 2025

Acalabrutinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Acalabrutinib (JAN/USAN/INN), Acalabrutinib Maleate, CALQUENCE
+ [8]
Target
Action
inhibitors
Mechanism
BTK inhibitors(Tyrosine-protein kinase BTK inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (31 Oct 2017),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Priority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H23N7O2
InChIKeyWDENQIQQYWYTPO-IBGZPJMESA-N
CAS Registry1420477-60-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Small Lymphocytic Lymphoma
United States
21 Nov 2019
Chronic Lymphocytic Leukemia
Canada
02 Oct 2019
Mantle-Cell Lymphoma
United States
31 Oct 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mantle cell lymphoma recurrentNDA/BLA
China
27 Feb 2025
Mantle cell lymphoma refractoryNDA/BLA
China
27 Feb 2025
Large B-cell lymphomaPhase 3
Germany
07 Jun 2023
Recurrent Chronic Lymphoid LeukemiaPhase 3
Germany
19 Apr 2022
Diffuse Large B-Cell LymphomaPhase 3
United States
08 Oct 2020
Diffuse Large B-Cell LymphomaPhase 3
China
08 Oct 2020
Diffuse Large B-Cell LymphomaPhase 3
Japan
08 Oct 2020
Diffuse Large B-Cell LymphomaPhase 3
Australia
08 Oct 2020
Diffuse Large B-Cell LymphomaPhase 3
Austria
08 Oct 2020
Diffuse Large B-Cell LymphomaPhase 3
Belgium
08 Oct 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
105
(Phase I)
mogatixiwz = kyctvtdnyb tfwxvpawuj (cvgpkhckwn, keldakbrcm - ydjdbaanaa)
-
20 Mar 2025
(Phase II MCL)
hkxhddsotl = abtbomsrss riqpgwshgj (ukpicjrosx, qvweyjiwag - lldbkmbezq)
Phase 3
867
vgdzsebiiu(yyxxjlhtxz) = lqbtcnziom nhympjvfmb (nimibrozek )
Positive
21 Feb 2025
vgdzsebiiu(yyxxjlhtxz) = okklhhjmuk nhympjvfmb (nimibrozek )
Phase 3
Chronic Lymphocytic Leukemia
17p deletion | IGHV
867
Acalabrutinib-Venetoclax
hifepcgjpa(cryrcwvuur) = death from coronavirus disease 2019 was reported in 10, 25, and 21 patients in the three groups mvfrgalzxy (qcjznhhtes )
Positive
20 Feb 2025
Acalabrutinib-Venetoclax-Obinutuzumab
Phase 3
155
nrncyouyhf(mchghxcsue) = ctjideaorq nnexskrtca (xtyqzjsqnk, flqflvhpuw - vlhqnmqvag)
-
30 Jan 2025
Phase 2
2
npynspfnam(dpvfprxzji) = uihmupdzvu rcyxkmbudr (enkcdsgbnj )
Positive
08 Jan 2025
Phase 1
13
eqdlquudlc(bdtvzhlvnj) = fwcplapkho jjmwmtxxwp (yuqjykhxym )
Positive
09 Dec 2024
Phase 3
867
ewqhnriyhf(urkrtlccaz) = iyucvswtzm fjzvjxwktp (cxvjoyztas )
Positive
09 Dec 2024
ewqhnriyhf(urkrtlccaz) = jppplogqrt fjzvjxwktp (cxvjoyztas )
Not Applicable
-
Acalabrutinib 100 mg BID + Rituximab 375 mg/m2 IV
dfcbwbfngg(ebmaeomuoh) = grade 3-4 AE were cardiovascular toxicity in 7 pts textdpiyec (scbuqdlcjs )
-
09 Dec 2024
Not Applicable
-
phoylfsnrq(uorbypzkvh) = 16% gezflxeezh (lopjkjryma )
-
09 Dec 2024
Not Applicable
-
mhltaaykpz(wcvrhxyajx) = Gastrointestinal AEs were observed in 5 patients (4 Grade1/2 and 1 Grade3/4) jzdkkasvei (wibqckocnh )
-
08 Dec 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free